AVBP

ArriVent BioPharma, Inc. Common Stock (AVBP) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Balance Sheet Liquidity

Very high liquidity with a current ratio of 14.16x and cash ratio of 5.56x.

Leverage remains minimal, with debt-to-equity at 0.001x and debt-to-assets at 0.001x.

Net current asset value of $366.3M and tangible book value per share of $7.71 provide downside support.

Profitability Cash Flow

Trailing margins remain unprofitable, with EBITDA, EBIT, and net profit margins all at 0% and net income per share at -$3.44.

Cash generation is negative, with operating cash flow per share at -$3.11 and free cash flow per share at -$3.11.

Returns remain deeply negative, including ROE of -50.3% and ROIC of -47.9%.

Valuation Downside Protection

The stock screens at a low EV of $1.22B versus a market cap of $1.37B, but valuation is distorted by negative earnings and cash flow.

Price-to-book is 3.83x, while book value per share is $7.71 and cash per share is $7.84.

Net current asset value of $366.3M and tangible asset value of $366.8M offer some asset-backed support despite weak operating performance.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ArriVent BioPharma, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →